Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

Corynoxeine

  • Zoom
    Corynoxeine
  • Corynoxeine
Cat No: 31403
Biochemicals - Natural Products
Cayman

Corynoxeine is an alkaloid that has been found in Uncaria and has diverse biological activities.{57268,57269,57270,45602} It inhibits LPS-induced production of nitric oxide (NO) in primary rat microglia (IC50 = 15.7 µM).{57268} Corynoxeine (5-50 µM) i...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • (?E,1?R,6?R,7?S,8?aS)-6'-ethenyl-1,2,2?,3?,6?,7?,8?,8?a-octahydro-?-(methoxymethylene)-2-oxo-spiro[3H-indole-3,1?(5?H)-indolizine]-7?-acetic acid, methyl ester
Correlated keywords:
  • Corynoxein ?18 Rhyncophylline PDGFBB ERK 1/2 LAD2 rhynchophylla
Product Overview:
Corynoxeine is an alkaloid that has been found in Uncaria and has diverse biological activities.{57268,57269,57270,45602} It inhibits LPS-induced production of nitric oxide (NO) in primary rat microglia (IC50 = 15.7 µM).{57268} Corynoxeine (5-50 µM) inhibits PDGF-BB-induced ERK1/2 activation in, and proliferation of, rat aortic vascular smooth muscle cells (VSMCs).{57269} It inhibits histamine release from LAD 2 mast cells induced by compound 48/80 (Item No. 22173) when used at concentrations ranging from 25 to 200 µM.{57270} In vivo, corynoxeine (0.5, 2.5, and 5 mg/kg) reduces compound 48/80-induced local anaphylaxis and mast cell degranulation in mouse hind paws. Corynoxeine (30 and 100 mg/kg) also reduces methamphetamine-induced hyperlocomotion in mice.{45602}
Size 1 mg
Shipping dry ice
CAS Number 630-94-4
Molecular Formula C22H26N2O4
SMILES O=C1[C@]2(C3=CC=CC=C3N1)[C@@]4([H])N(C[C@@H]([C@H](C4)/C(C(OC)=O)=C\OC)C=C)CC2
Molecular Weight 382,5
Formulation A solid
Purity ≥98%
Custom Code 2933.79
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

Search